Rilotumumab
Based on 1 Customer Validation
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.10%
- CAS. Nr.: 872514-65-3
- Molecular Weight:145.2 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Human IgG2 kappa
Human
HGF/SF
Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U87MG.vIII cells
-
Concentration:10 μg/mL
-
Incubation Time:Overnight
-
Result:Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells.
Showed an increase in total MET compared with untreated cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells[2]
-
Dosage:1.5 mg/kg
-
Administration:Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
-
Result:Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized Human HGF Protein (C-6His) can bind Rilotumumab. The EC50 for this effect is 13.45 ng/mL.
Chemical Information
-
CAS. Nr. 872514-65-3
-
Appearance Liquid
-
Molecular Weight 145.2 kDa
-
Color Colorless to light yellow
-
SMILES
[Rilotumumab]
-
Synonyms
AMG 102
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. [Content Brief]
[2]. Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Rilotumumab Related Classifications
HY-P99217 Related Classifications
Powered by Bioz